Propranolol hydrochloride 是非选择性的β-Adrenergic Receptor拮抗剂，对 β1AR 和 β2AR 具有高亲和力。它能够抑制 [3H]-DHA 与大鼠脑膜制剂的结合。它可以用于研究高血压，嗜铬细胞瘤，心肌梗塞，心律不齐，心绞痛和肥大心肌病。

Propranolol hydrochloride is a widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.

In cultured endothelial or tumor cells, propranolol has been shown to both reduce cAMP levels and simultaneously activate the mitogen-activated protein kinase (MAPK) pathway downstream of βAR inhibition[2]. It displays high affinity for 5-HT1B receptors (Ki= 17 nM), and milder affinity for 5HT1D receptors (Ki= 10.2 μM)[3].

Chronic administration of propranolol increased the beta(1)-adrenoceptors but decreased the beta(2)-adrenoceptors without changing total amount of plasma membrane beta-adrenoceptors[4].

318-98-9

C16H22ClNO2

295.81

Propranolol HCl;NCS-91523;ICI-45520;AY-64043;盐酸普萘洛尔

H2O:6 mg/mL (20.28 mM)
DMSO:55 mg/mL (185.9 mM)
Ethanol:<1 mgml
Powder: -20°C for 3 years
In solvent: -80°C for 2 years